Dimensional Fund Advisors LP Purchases 169,427 Shares of Hologic, Inc. (NASDAQ:HOLX)

Dimensional Fund Advisors LP grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 6.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,625,290 shares of the medical equipment provider's stock after purchasing an additional 169,427 shares during the period. Dimensional Fund Advisors LP owned about 1.16% of Hologic worth $189,264,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in HOLX. Brooklyn Investment Group grew its stake in shares of Hologic by 14.7% in the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 145 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the period. Trivant Custom Portfolio Group LLC increased its stake in shares of Hologic by 2.1% during the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after purchasing an additional 169 shares during the period. UMB Bank n.a. boosted its stake in Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after purchasing an additional 188 shares during the period. Finally, Capital Investment Counsel Inc increased its position in Hologic by 3.6% during the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock worth $413,000 after buying an additional 200 shares during the period. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Shares of NASDAQ:HOLX traded up $0.19 during trading on Tuesday, hitting $58.27. 238,965 shares of the company were exchanged, compared to its average volume of 1,962,052. Hologic, Inc. has a 1-year low of $55.89 and a 1-year high of $84.67. The company has a market capitalization of $13.08 billion, a P/E ratio of 18.38, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The business's 50 day moving average is $60.90 and its 200-day moving average is $69.77.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Raymond James reaffirmed an "outperform" rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley reduced their price target on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective for the company. in a report on Monday, February 3rd. Stephens reissued an "overweight" rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Finally, Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Hologic currently has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.